Saltar al contenido principal
xMedica

NCT06628908ClinicalTrials.gov

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

Fase 31100 participantes buscados76 centros1 país

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 7 days after the recorded start)First posted 2024-10-08; recorded start 2024-10-01
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 92 other studies in this databaseCounted from the lead sponsor named in the record (Vertex Pharmaceuticals Incorporated)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 76 sites

  • Data monitoring committee0/7

    Data monitoring committee not stated in the record

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,100 participants (target), run at 76 sites.

How this score is built
  • Enrolment30/40

    1,100 participants (target)

  • Site count22/25

    76 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 32 months

  • Sponsor scale7/10

    Vertex Pharmaceuticals Incorporated has led 90 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

Afecciones

  • Diabetic Peripheral Neuropathic Pain

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years80 Years
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Key Inclusion Criteria: * Body weight greater than or equal to (≥) 45 kilogram (kg) * Body mass index (BMI) ≥18.0 to less than (\<) 40.0 kilogram per meter square (kg/m\^2) * Diagnosis of diabetes mellitus type 1 or type 2 by glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pain in lower extremities due to DPN * Weekly average of daily NPRS score ≥4 and less than or equal to (≤) 9 with limited variation in the 7-day Baseline Period Key Exclusion Criteria: * More than 3 missing daily NPRS scores during the 7-day Baseline Period * Any sensory abnormality (excluding DPN) as pre-specified in the protocol Other protocol defined Inclusion/Exclusion criteria may apply.

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseFase 3
AsignaciónAleatorizado
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoQUADRUPLE (4)
Inscripción1100 participantes buscados

Patrocinador y colaboradores

  • Vertex Pharmaceuticals Incorporated Patrocinador

Grupos e intervenciones

  • Suzetrigine (SUZ)EXPERIMENTAL

    Participants will be randomized to receive SUZ.

  • PregabalinACTIVE_COMPARATOR

    Participants will be randomized to receive Pregabalin.

  • PlaceboPLACEBO_COMPARATOR

    Participants will be randomized to receive placebo matched to SUZ and Pregabalin.

Intervenciones

  • Fármaco Placebo (matched to Pregabalin)

    Placebo matched to Pregabalin for oral administration.

  • Fármaco Placebo (matched to SUZ)

    Placebo matched to SUZ for oral administration.

  • Fármaco Pregabalin

    Capsules for oral administration.

  • Fármaco Suzetrigine

    Tablets for oral administration.

Variables de resultado

  1. Variable de resultado principal

    Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo

    Plazo From Baseline up to Week 12

  2. Variable de resultado secundaria

    Change From Baseline in the Medical Outcomes Study 36-item Short-form Health Status (SF 36v2) Physical Component Summary (PCS) Score at Week 12 Compared to Placebo (pooled with data from Study VX24-548-111)

    Plazo From Baseline up to Week 12

  3. Variable de resultado secundaria

    Change From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS at Week 12 Compared to Pregabalin

    Plazo From Baseline up to Week 12

Fechas

Fechas
Fecha de inicio1 de octubre de 2024 (real)
Finalización principal31 de mayo de 2027 (estimada)
Finalización31 de mayo de 2027 (estimada)
Primera publicación8 de octubre de 2024 (real)
Última actualización15 de junio de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última vezjunio de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

59 centros están en reclutamiento

United States

United States
CentroCiudadEstado o regiónEstado
Albany Medical CollegeAlbanyNew YorkCompletado
Velocity Clinical Research - AlbuquerqueAlbuquerqueNew MexicoEn reclutamiento
Synexus Clinical Research- AndersonAndersonSouth CarolinaCompletado
Pinnacle Research Group, LLCAnnistonAlabamaEn reclutamiento
Velocity Clinical Research - Baton RougeBaton RougeLouisianaEn reclutamiento
Velocity Clinical Research - ClevelandBeachwoodOhioEn reclutamiento
Northwest Clinical Research Center (NWCRC)BellevueWashingtonEn reclutamiento
Synexus Clinical Research - BirminghamBirminghamAlabamaCompletado
Mass General Brigham - Brigham and Women's Hospital - Main CampusBostonMassachusettsEn reclutamiento
Swift Clinical OpCo, IncBrooklynNew YorkEn reclutamiento
Clinical Trials of South Carolina - Berkeley - CharlestonCharlestonSouth CarolinaEn reclutamiento
M3 Wake Research - CharlestonCharlestonSouth CarolinaEn reclutamiento
Feinberg School of Medicine - AnesthesiologyChicagoIllinoisEn reclutamiento
Synexus Clinical Research - CincinnatiCincinnatiOhioCompletado
Tandem Clinical Research- CovingtonCovingtonLouisianaEn reclutamiento
Synexus Clinical Research - Dallas (DFW) (DRS)DallasTexasCompletado
Zenos Clinical ResearchDallasTexasEn reclutamiento
AMR Daphne, ALDaphneAlabamaCompletado
META Medical Research InstituteDaytonOhioEn reclutamiento
Accel Research - DelandDeLandFloridaEn reclutamiento
Accel Research - DecaturDecaturGeorgiaEn reclutamiento
AMR-MiamiDoralFloridaEn reclutamiento
Velocity Clinical Research - ProvidenceEast GreenwichRhode IslandEn reclutamiento
Velocity Clinical Research - SyracuseEast SyracuseNew YorkEn reclutamiento
Velocity Clinical Research - DenverEnglewoodColoradoEn reclutamiento
Synexus Clinical Research - EvansvilleEvansvilleIndianaCompletado
Healthcare Research Network - Flossmoor ILFlossmoorIllinoisEn reclutamiento
AMR Fort Myers (The Clinical Study Center)Fort MyersFloridaEn reclutamiento
Neuro-Pain Medical CenterFresnoCaliforniaEn reclutamiento
Velocity Clinical Research - Grants PassGrants PassOregonCompletado
Velocity Clinical Research - Hallandale BeachHallandaleFloridaEn reclutamiento
Healthcare Research Network - Hazelwood MOHazelwoodMissouriEn reclutamiento
CNS Healthcare - JacksonvilleJacksonvilleFloridaEn reclutamiento
AMR Kansas CityKansas CityMissouriEn reclutamiento
Accel Research - St. Petersburg-LargoLargoFloridaEn reclutamiento
Synexus Clinical Research - Las VegasLas VegasNevadaCompletado
AMR LexingtonLexingtonKentuckyEn reclutamiento
Long Beach Research InstituteLong BeachCaliforniaEn reclutamiento
Angel City Research, IncLos AngelesCaliforniaEn reclutamiento
Accel Research - MaitlandMaitlandFloridaCompletado
HRI - Hassman Research InstituteMarltonNew JerseyCompletado
Velocity Clinical Research - MedfordMedfordOregonEn reclutamiento
Suburban Research Associates - MediaMediaPennsylvaniaEn reclutamiento
Velocity Clinical Research - BoiseMeridianIdahoEn reclutamiento
Suncoast Research Associates - MiamiMiamiFloridaEn reclutamiento
3Sync Research - Miami LakesMiami LakesFloridaEn reclutamiento
West Clinical ResearchMorehead CityNorth CarolinaEn reclutamiento
AMR Nashville, TNNashvilleTennesseeCompletado
Suncoast Clinical Research - New Port RicheyNew Port RicheyFloridaEn reclutamiento
Columbia Presbyterian - The Neurological Institute of New YorkNew YorkNew YorkEn reclutamiento

En el registro figuran 26 centros más.

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

No se han registrado cambios desde que incorporamos este registro por primera vez.

Se registra un cambio cada vez que el patrocinador actualiza el registro. El estado, las fechas, la inscripción y los centros aparecen aquí a medida que cambian.